Precigen, Inc. (PGEN)

NASDAQ: PGEN · IEX Real-Time Price · USD
2.48
-0.15 (-5.53%)
Aug 16, 2022 11:37 AM EDT - Market open
-5.53%
Market Cap 515.17M
Revenue (ttm) 80.71M
Net Income (ttm) -91.68M
Shares Out 208.15M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 347,173
Open 2.59
Previous Close 2.62
Day's Range 2.44 - 2.61
52-Week Range 1.12 - 6.46
Beta 2.28
Analysts Buy
Price Target 12.44 (+402.6%)
Earnings Date Aug 8, 2022

About PGEN

Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorporates advanced DNA construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbIL15, a gene that enhances functional characteristic... [Read more...]

Industry Biotechnology
Founded 1998
CEO Helen Sabzevari
Employees 456
Stock Exchange NASDAQ
Ticker Symbol PGEN
Full Company Profile

Financial Performance

In 2021, Precigen's revenue was $103.87 million, an increase of 0.67% compared to the previous year's $103.18 million. Losses were -$92.17 million, -45.95% less than in 2020.

Financial Statements

Analyst Forecast

According to 11 analysts, the average rating for PGEN stock is "Buy." The 12-month stock price forecast is 12.44, which is an increase of 402.63% from the latest price.

Price Target
$12.44
(402.63% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Precigen, Inc. (PGEN) Reports Q2 Loss, Lags Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 18.75% and 83.41%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Precigen Reports Second Quarter and First Half 2022 Financial Results

– Enrollment  complete in Phase 1 study of PRGN-3006 UltraCAR-T ® in acute myeloid leukemia (AML); enrollment ongoing in Phase 1b dose expansion study; Mayo Clinic in Rochester, Minnesota activated as f...

Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th

GERMANTOWN, Md., Aug. 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pat...

Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen, Inc. (PGEN) Upgraded to Buy: Here's What You Should Know

Precigen, Inc. (PGEN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

This Analyst Believes Precigen's Non-Healthcare Divesture Removes Financial Overhang

Yesterday, Precigen Inc (NASDAQ: PGEN) agreed to sell its non-healthcare subsidiary to URUS. HC Wainwright says they are encouraged by the divestiture of the company's non-core business and believe mana...

Why Precigen Shares Are Gaining Today

Precigen Inc (NASDAQ: PGEN) has agreed to sell its subsidiary Trans Ova Genetics, an animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership. The deal...

Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics

–  Precigen enters into agreement to sell wholly-owned subsidiary Trans Ova Genetics to URUS for $170 million in upfront cash and up to $10 million earn-out over two years; close expected in Q3 2022 – –...

Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit

GERMANTOWN, Md. , June 27, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of p...

Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference

GERMANTOWN, Md. , May 17, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pa...

Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 28.57% and 53.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Precigen Reports First Quarter 2022 Financial Results and Business Updates

– Fast Track designation received for PRGN-3006 UltraCAR-T®, an important milestone for patients with relapsed or refractory acute myeloid leukemia, a rapidly progressing disease with limited treatment ...

Precigen, Inc. (PGEN) Expected to Beat Earnings Estimates: Should You Buy?

Precigen, Inc. (PGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Precigen (PGEN) Up on FDA Fast Track Tag for CAR-T Candidate

Precigen (PGEN) is developing CAR T therapy candidate, PRGN-3006 UltraCAR-T, for treating acute myeloid leukemia in a phase I study. The FDA grants Fast Track designation.

Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myel...

–   Acute myeloid leukemia (AML) is among the most common types of leukemia in adults – –   PRGN-3006 UltraCAR-T previously  received orphan drug designation (ODD) in patients with AML by the US Food an...

PRECIGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Precigen, Inc. f/k/a Intrexon Corporation on Behalf of L...

NEW YORK--(BUSINESS WIRE)-- #Class--Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Precigen, Inc. f/k/a Intrexon Corporation ...

Precigen, Inc. (PGEN) Reports Q4 Loss, Tops Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 7.14% and 14.63%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Precigen Reports Fourth Quarter and Full Year 2021 Financial Results

GERMANTOWN, Md., March 1, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pa...

Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md., Jan. 12, 2022 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of pa...

Here's Why Precigen, Inc. (PGEN) Could be Great Choice for a Bottom Fisher

Precigen, Inc. (PGEN) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among W...

Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference

GERMANTOWN, Md. , Jan. 5, 2022 /PRNewswire/ --  Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of p...

3 Synthetic Biology Stocks in Focus With Strong Potential

Here we discuss three stocks - CDXS, PGEN, VERV - engaged in the field of scientific biology that investors may keep a tab of as these have the potential to generate wealth for them going forward.

Other symbols: CDXSVERV

Precigen Reveals Early Data From CAR-T Candidate In Blood Cancer Patients

Precigen Inc (NASDAQ: PGEN) presented positive interim data at the ASH Annual Meeting and Exposition from the ongoing Phase 1/1b study of PRGN-3006 UltraCAR-T in relapsed or refractory (r/r) acute myelo...

Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Le...

GERMANTOWN, Md., Dec. 13, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today p...

Is the Options Market Predicting a Spike in Precigen (PGEN) Stock?

Investors need to pay close attention to Precigen (PGEN) stock based on the movements in the options market lately.